WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2003000846) A NOVEL G PROTEIN-COUPLED RECEPTOR, GAVE 3
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2003/000846    International Application No.:    PCT/US2002/019490
Publication Date: 03.01.2003 International Filing Date: 21.06.2002
Chapter 2 Demand Filed:    22.01.2003    
IPC:
A61K 38/00 (2006.01), C07K 14/705 (2006.01)
Applicants: AVENTIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, NJ 08807-2854 (US)
Inventors: XIA, Tai-he; (US).
NI, Donghui; (US).
EISHINGDRELO, Haifeng; (US).
ARDATI, Ali; (US).
MINNICH, Anne; (US).
JUPP, Ray; (US)
Agent: NAKAMURA, Dean; Roylance, Abrams, Berdo & Goodman, L.L.P., 1300 19th Street, N.W., Suite 600, Washington, DC 20036 (US)
Priority Data:
09/886,041 22.06.2001 US
Title (EN) A NOVEL G PROTEIN-COUPLED RECEPTOR, GAVE 3
(FR) GAVE 3, NOUVEAU RECEPTEUR COUPLE A UNE PROTEINE G
Abstract: front page image
(EN)Novel GAVE3 polypeptides, proteins and nucleic acid molecules are provided. In addition to isolated, full-length GAVE3 proteins, isolated GAVE3 fusion proteins, antigenic peptides and anti-GAVE3 antibodies are taught. GAVE3, recombinant expression vectors, host cells into that the expression vectors have been introduced and non-human transgenic animals in that a GAVE3 gene has been introduced or disrupted are taught. Diagnostic, screening and therapeutic methods utilizing compositions of the invention also are provided.
(FR)L'invention se rapporte à de nouveaux polypeptides, protéines et molécules d'acide nucléique GAVE3. L'invention concerne également, outre des protéines GAVE3 pleine longueur isolées, des protéines de fusion GAVE3 isolées, des peptides antigéniques et des anticorps anti-GAVE3. L'invention concerne également GAVE3, des vecteurs d'expression recombinants, des cellules hôtes dans lesquelles les vecteurs d'expression ont été introduits et des animaux transgéniques non humains dans lesquels un gène GAVE3 a été introduit ou dissocié. L'invention a également trait à des procédés de diagnostic, de criblage et de thérapie utilisant les compositions de l'invention.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)